Prognostic Role of MELD-Lactate in Cirrhotic Patients’ Short- and Long-Term Prognosis, Stratified by Causes of Cirrhosis
Table 3
Model discrimination for mortality, stratified by causes of cirrhosis.
AUROC (95% CI)
Causes of cirrhosis
Alcoholic and hepatitis (n = 59)
Alcoholic (n = 201)
Hepatitis (n = 64)
Mortality
15-day mortality
5-year mortality
15-day mortality
5-year mortality
15-day mortality
5-year mortality
Child-Pugh
0.592 (0.438–0.747)
0.707 (0.571–0.842)
0.563 (0.483–0.642)
0.542 (0.461–0.623)
0.505 (0.354–0.655)
0.548 (0.396–0.700)
SOFA
0.735 (0.583–0.887)
0.666 (0.525–0.807)
0.799 (0.734–0.863)
0.681 (0.606–0.756)
0.818 (0.711–0.926)
0.751 (0.632–0.870)
CLIF-SOFA
0.723 (0.575–0.872)
0.672 (0.532–0.813)
0.781 (0.713–0.850)
0.666 (0.590–0.742)
0.801 (0.679–0.924)
0.756 (0.635–0.877)
MELD
0.755 (0.619–0.891)
0.749 (0.617–0.881)
0.787 (0.720–0.853)
0.721 (0.649–0.794)
0.714 (0.578–0.851)
0.750 (0.627–0.873)
MELD-LA
0.783 (0.651–0.915)
0.678 (0.535–0.820)
0.805 (0.743–0.867)
0.732 (0.660–0.803)
0.762 (0.627–0.897)
0.750 (0.628–0.872)
DeLong test was used to compare the AUC between MELD-LA and other clinical models. AUROC, area under the receiver operating characteristic curve; CI, confidence interval; SOFA, sequential organ failure assessment; CLIF-SOFA, chronic liver failure-sequential organ failure assessment; MELD, model for end-stage liver disease; MELD-LA, model for end-stage liver disease-lactate.
